Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics

Acurx Pharmaceuticals, Inc. (ACXP): $2.51

0.10 (-3.83%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ACXP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#253 of 360

in industry

ACXP Price/Volume Stats

Current price $2.51 52-week high $8.82
Prev. close $2.61 52-week low $1.17
Day low $2.51 Volume 35,200
Day high $2.64 Avg. volume 138,481
50-day MA $2.12 Dividend yield N/A
200-day MA $2.91 Market Cap 39.77M

ACXP Stock Price Chart Interactive Chart >


Acurx Pharmaceuticals, Inc. (ACXP) Company Bio


Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.


ACXP Latest News Stream


Event/Time News Detail
Loading, please wait...

ACXP Latest Social Stream


Loading social stream, please wait...

View Full ACXP Social Stream

Latest ACXP News From Around the Web

Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced positive Phase 2b results showing 100% of CDI patients who had CC with ibezapolstat, the company's late-stage antibiotic candidate, also had SCC.

Yahoo | December 11, 2023

New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT

New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT Episode 537: 1). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4).The Business of Blockchain, 5).Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com/ NEW YORK, Dec. 08, 202

Yahoo | December 8, 2023

New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT

New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT Episode 536: 1). - Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4). The Business of Blockchain 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne

Yahoo | December 7, 2023

New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT

New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT Episode 535: 1).Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 3).American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4).PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne

Yahoo | December 1, 2023

New to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT

New to The Street Announces its Five Business Guest Interviews, Episode 533, which airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT Episode 533 will air the following five (5) business interviews: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Coastal Kapital, LLC. 3). American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (

Yahoo | November 24, 2023

Read More 'ACXP' Stories Here

ACXP Price Returns

1-mo 21.26%
3-mo -19.81%
6-mo -29.89%
1-year -13.45%
3-year N/A
5-year N/A
YTD -34.46%
2023 -3.77%
2022 -7.90%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!